BRD4 and gastric neoplasm: Taken together, these observations indicate that BET inhibitors, which potentially interfere with BRD4 recruitment to the ALDH1A3 promoter, decrease DTP cell survival and enhance chemotherapeutic efficacy against gastric tumors in vivo (Fig. 6H).